ALXN - PhaseBio shares spike 22% in afternoon trading

Shares of PhaseBio Pharmaceuticals (PHAS) are up more than 22% in early afternoon trading.There doesn't appear to be any news or other catalyst to explain the spike.Johnson & Johnson (JNJ) and AstraZeneca (AZN) own stakes in the microcap stock which has a market cap of just $133M.A Stifel analyst previously noted that the Alexion Pharmaceuticals (ALXN) acquisition of Portola Pharmaceuticals, which closed in July 2020, "should bring attention to PhaseBio's currently underappreciated lead asset PB2452."PB2452, also known as bentracimab, is currently in phase 3 for the reversal of the antiplatelet activity of the blood thinner Brilinta.PhaseBio also has PB1046 (pemziviptadil) in phase 2 for pulmonary arterial hypertension.PhaseBio shares are up 22.3% to $5.54 in afternoon trading

For further details see:

PhaseBio shares spike 22% in afternoon trading